TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03573583

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Training
Description: The intensity, volume, tempo, and progression will be based on the Federal Physical Activity guidelines. The resistance training exercises will include mainly multi-joint exercises using selectorized machines. Each session will include upper body exercises (Chest Press, Shoulder Press, Seated Rows, Bicep curls, and Tricep Extensions) and lower body exercises (Leg Press, Leg Extension and Leg Curls, and Calf raise) that will be tailored to the participant needs.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Successful Aging
Description: The successful aging will attend stretching and health lectures as a group . The topics might include, medication management, disease management (e.g. blood pressure, diabetes, arthritis, dementia, pain management, diet) and other health related matters.
Study: NCT02943291

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 4x4 minutes high intensity interval training
Description: Treadmill running/walking with 10 minutes warm-up at 60-70% of maximum heart rate, 4x4 minute intervals at 90-95% of maximum heart rate separated by 3-minutes active pauses at 60-70% of maximum heart rate, and 3 minutes cool-down.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 10x1 minute high intensity interval training
Description: Treadmill running/walking with 10 minutes warm-up at 60-70% of maximum heart rate, ten 1-minute intervals at maximal intensity (that can be performed for one minute), separated by 1-minutes active pauses at 60-70% of maximum heart rate, and 3 minutes cool-down.
Study: NCT00808054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EMLA
Description: 0.5g topical EMLA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EMLA
Description: 0.5g topical EMLA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EMLA
Description: 0.5g topical EMLA
Study: NCT00574873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosutinib
Description: 500 mg once daily, by mouth (tablet) with food preferably in the morning. Drug can be increased up to 600mg daily in case of lack of efficacy, and can be reduced to 300mg daily in case of toxicity. The drug will be given daily for up to 8 years until treatment failure, unacceptable toxicity, death or withdrawal of consent.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: imatinib
Description: 400 mg once daily, by mouth (tablet). Drug can be increased up to 600mg daily in case of lack of efficacy, and can be reduced to 300mg daily in case of toxicity. The drug will be given daily for up to 8 years until treatment failure, unacceptable toxicity, death or withdrawal of consent.
Study: NCT00285428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hA20-humanized anti-CD20 antibody
Description: once weekly iv dosing for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hA20-humanized anti-CD20 antibody
Description: once weekly iv dosing for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hA20-humanized anti-CD20 antibody
Description: once weekly iv dosing for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hA20-humanized anti-CD20 antibody
Description: once weekly iv dosing for 4 weeks
Study: NCT00828477

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xibrom
Description: Xibrom: two times a day for seven days in the first eye.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nevanac
Description: Nevanac: three times a day for seven days in the second eye.
Study: NCT04669353

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Platelet rich plasma
Description: approximately 15 cm of whole blood was drawn from the uninvolved arm of each patient in the intervention group (group I) into a 20 ml sterile syringe containing citrate for anticoagulation. The blood was immediately centrifuged at 3200 Revolutions per Minute (PRM). Following 15 minutes of centrifugation, 4 - 5 mL of PRP was obtained. Then, the PRP was buffered by using sodium bicarbonate.
Study: NCT01543984

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tailored Physical Activity
Description: Tailored Physical Activity (3\*50 min/week in 10 weeks)

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Health Counselling
Description: Health guidance (1,5h)
Study: NCT00597246

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FACBC, Methionine
Description: F-18 labeled FACBC is prepared stereo-specifically in a semi-automated, NCA procedure utilizing the General Electric FDG MicroLab, a system employing a quaternary 4-aminopyridinium resin to effect F-18 fluorination. The triflate species is displaced with F-18 fluoride in the MicroLab, and then the 1-t-butyl carbamate-3- trifluoromethane sulfonoxy-1-cyclobutane-1-carboxylic acid methyl ester is hydrolyzed with 1 N HCl. The final product is isotonic and sterile, and has been utilized in animal experiments. The product was obtained in 30% radiochemical yield after 65 minutes from EOB. The radiochemical purity was greater than 95% and no preparative HPLC was required. The procedure could be considered routine, and is performed on the FDG synthetic module without changes either to the programming or to the cassettes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PET Scan
Description: GE Advance PET scanner for sequential body imaging
Study: NCT01329692

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle counseling
Description: Weeks 1 and 2 consist primarily of a review of current dietary habits with initiation of a food journal; a basic review of macronutrients and metabolism; and the beginning of a weekly exercise regimen. Weeks 3, 4, \& 5 introduces counseling, with specific emphasis on emotional aspects of eating and behavioral modification strategies. Week 6 focuses on the metabolic impact of exercise, and includes an exercise session with a personal trainer. Week 7 incorporates a question and answer session with a sharing of discoveries, as well as an option for additional individual follow-up as needed. During this period, patients will also be given access to an interactive web-based tool providing additional emphasis on the aforementioned components and clinician follow-up.
Study: NCT00964587

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education + Problem-Solving Training Self-Study
Description: * Education + Problem-Solving Training Self-Study~* One session of Literacy-Adapted Diabetes and CVD Risk Education~* Instructions and a schedule for use of the Literacy-Adapted Problem-Solving Workbook for self-study will be given to each participant.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education + Group Problem-Solving Training
Description: * Education + Group Problem-Solving Training~* One session of the Literacy-Adapted Diabetes and CVD Risk Education~* Group problem-solving training eight, 90-minute sessions

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education + Individual Problem-Solving Training
Description: * Education + Individual Problem-Solving Training~* One session of the Literacy-Adapted Diabetes and CVD Risk Education~* Individual problem-solving training (eight, 60-minute sessions)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: * Packet of print patient education materials about CVD and diabetes from the American Heart Association (AHA) and the American Diabetes Association (ADA)given at baseline following randomization to Arm 1~* Scripted set of instructions will be given along with a verbal description of the materials and the content provided.
Study: NCT04521569

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regadenoson
Description: If the donor lungs are randomized the experimental arm, the administration of Regadenoson will be performed at each study site by a qualified medical professional. The donor lungs will be perfused with Regadenoson at a dosage of 1.44 microgram/kg/min (based on donor's weight) for a minimum of three hours and maximum of four hours, using a pediatric syringe pump into the EVLP circuit (XVIVO Perfusion System). The infusion will begin within 10 minutes of the start of the EVLP procedure. Once the EVLP is complete the lungs are re-flushed with Perfadex solution (removing the Steen™ solution and Regadenoson; standard for EVLP).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: If the donor lungs are randomized to the Steen solution arm, the donor lungs will be perfused with placebo at a rate equivalent to the dosage of Regadenoson (1.44 microgram/kg/min), for a minimum of three hours and maximum of four hours, using the same pediatric syringe pump. The infusion will begin within 10 minutes of the start of the EVLP procedure.
Study: NCT02054585

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NaCl 0.9 +5% dextrose
Description: Children will be included in each group in a randomized way using SAS (Statistical Analysis System) program.~Intervention: In this arm children will receive 20 ml/kg bolus of IV NaCl 0.9% + 5% dextrose. The bags will be identical and the content will be 1 liter. This way if a second bolus is administrated before hospitalization or discharge is decided, the child will still receive the same fluid.
Study: NCT03446781

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: EN3835
Description: Collagenase clostridium histolyticum

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04450017

Intervention type: DIAGNOSTIC_TEST
Intervention: The demographic, clinical, laboratory, and instrumental data
Description: Measurement of the demographic, clinical data, laboratory data, and instrumental data
Study: NCT01593345

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobility self-management with Mentor
Description: will be offered an evaluation and treatment plan supervised by a qualified physiotherapist, accompanied by written and visual material to enhance mobility self-management skills, supported by telephone mentoring by physiotherapy students in the Professional Master's program. The components of the mobility self-management program will target skill enhancement of each senior to identify their functional limitations, set realistic goals for mobility improvement, develop a mobility action plan, carry out the plan, and then re-assess their function and mobility. Mobility self-assessment, personalized goals, and the action plan will be incorporated into a personalized workbook that the senior can use to monitor their function profile and serve as a communication aid during health care encounters.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mobility self-management with guidebook
Description: will be mailed an exercise guide targeting the key mobility limitations common in the elderly (range of motion, arm, leg, and core strength, and breathing). This guide has been developed and has been pilot tested on a small number of seniors and has been shown to be acceptable and feasible.
Study: NCT02508220

Intervention type: DRUG
Group type: OTHER
Intervention: Syntocinon
Description: Oxytocin nasal spray

Intervention type: DRUG
Group type: OTHER
Intervention: Syntocinon
Description: Oxytocin nasal spray

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: distilled water in nasal spray

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: distilled water in nasal spray
Study: NCT04680338

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: CMR stress perfusion imaging
Description: CMR stress perfusion imaging with feedback of clinically actionable findings to general practitioner and participant
Study: NCT03724994

Intervention type: DRUG
Intervention: Gemcitabine
Description: Adjuvant or palliative chemotherapy according to national guidelines
Study: NCT01346475

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: valacyclovir
Description: 1000 mg orally three times daily for 5 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valacyclovir
Description: 500 mg orally once daily for 5 weeks
Study: NCT04147117

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cervical pessary
Description: Cervical pessary is a silicone ring with a smaller diameter to be fitted around the cervix and a larger diameter to fix the device to the pelvic floor. It modifies the direction of the cervix to the posterior vaginal wall.
Study: NCT00873431

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IC47
Description: solution/suspension for i.m. injection dosage: 30/150 mcg frequency: 3 times at Day 0, Day 42 and Day 84

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IC47
Description: solution/suspension for i.m. injection dosage: 30/150 mcg frequency: 3 times at Day 0, Day 42 and Day 84

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IC47
Description: solution/suspension for i.m. injection dosage: 30/150 mcg frequency: 3 times at Day 0, Day 42 and Day 84

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IC47
Description: solution/suspension for i.m. injection dosage: 30/150 mcg frequency: 3 times at Day 0, Day 42 and Day 84
Study: NCT00531739

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Polylactic Acid Sheet
Description: SurgiWrapTM film will be secured in two study areas: directly below the abdominal incision and on the posterior pelvic rim. The film will not be wrapped directly around an anastomosis.
Study: NCT01739842

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Kudzu extract

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Kudzu extract
Study: NCT03927573

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GEM3PSCA
Description: Infusion of GEM3PSCA, administered intravenously, continuously over 7 days, 2 cycles
Study: NCT03455621

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Toothbrushing
Description: Toothbrushing with different amounts of fluoride toothpaste (or a non-fluoride toothpaste as a control)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Toothbrushing
Description: Toothbrushing with different amounts of fluoride toothpaste (or a non-fluoride toothpaste as a control)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Toothbrushing
Description: Toothbrushing with different amounts of fluoride toothpaste (or a non-fluoride toothpaste as a control)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Toothbrushing
Description: Toothbrushing with different amounts of fluoride toothpaste (or a non-fluoride toothpaste as a control)

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Toothbrushing
Description: Toothbrushing with different amounts of fluoride toothpaste (or a non-fluoride toothpaste as a control)
Study: NCT00621777

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: At each weekly study visit from the baseline visit to study week 11, ALL subjects will receive a one-week supply of varenicline with instructions on how to take the study medication. Titration is as follows: 0.5 mg varenicline per day for 3 days, then 0.5 mg twice per day for 4 days, and then 1 mg twice per day for 11 weeks.~In addition, participants who enter the relapse prevention phase and are randomized to the varenicline condition will receive varenicline at the dose used to attain initial abstinence for 40 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: At each weekly study visit from the baseline visit to study week 11,ALL subjects will receive a one-week supply of varenicline with instructions on how to take the study medication. Titration is as follows: 0.5 mg varenicline per day for 3 days, then 0.5 mg twice per day for 4 days, and then 1 mg twice per day for 11 weeks.~In addition, participants who enter the relapse prevention phase and are randomized to the placebo condition will receive placebo pills for 40 weeks.
Study: NCT02533817

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary sugar
Description: This study examined the effect of high intakes of fructose compared to high intakes of glucose in a randomized crossover design. The treatment was in replacement of 20% of the daily caloric requirements for either fructose or glucose for each individual.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dietary sugar
Description: This study examined the effect of high intakes of fructose compared to high intakes of glucose in a randomized crossover design. The treatment was in replacement of 20% of the daily caloric requirements for either fructose or glucose for each individual.
Study: NCT02324608

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03057990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrimethamine
Description: Pyrimethamine will be administered 50mg/100mg/150mg once daily on days 1-28 of each 28-day cycle. Administered using intra-patient dose escalation, starting at 50 mg and up to 150 mg.
Study: NCT04610541

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remdesivir-HU
Description: Remdesivir-HU 100 mg concentrate for solution for infusion
Study: NCT03303846

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo high risk breast cancer screening MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood and tissue sample collection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT02969239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Description: bolus administered norepinephrine 5mcg intravenously, if SBP \<90mmHg or 20% decrease from baseline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenylephrine
Description: bolus administered phenylephrine 100mcg intravenously, if SBP \<90mmHg or 20% decrease from baseline
Study: NCT04084184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP1812
Description: Dapagliflozin (Forxiga) 10mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP1812
Description: Dapagliflozin (Forxiga) 10mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP1602
Description: Dapagliflozin 10mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP1602
Description: Dapagliflozin 10mg
Study: NCT01239043

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Menomune®: A, C, Y, W 135 Meningococcal Polysaccharide
Description: 0.5 mL, Subcutaneous

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Menactra®: Meningococcal (A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate
Description: 0.5 mL, Intramuscular
Study: NCT00112827

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total marrow irradiation
Description: Undergo irradiation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Undergo transplantation

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given IV

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: fluorescence in situ hybridization
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: cytogenetic analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous-autologous tandem hematopoietic stem cell transplantation
Description: Undergo transplantation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Given orally
Study: NCT02874924

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapamycin
Description: treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: control

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapamycin
Description: No placebo control in this substudy group
Study: NCT03568487

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensive scapula-focused approach
Description: scapula-focused approach with exercises, 3 x 20 min training per week for 4 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Therapy
Description: not have any physical training but is encouraged to stay active as usual.
Study: NCT00692276

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Superion™ Interspinous Spacer
Description: Implantation of interspinous process spacer to treat lumbar spinal stenosis

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: X-STOP® IPD® Device
Description: Implantation of interspinous process spacer to treat lumbar spinal stenosis
Study: NCT01072760

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: K wire
Description: Mallet finger treatment
Study: NCT01033422

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CF101
Description: CF101 1 or 2 mg tablets orally every 12 hours for 16 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CF101
Description: CF101 1 or 2 mg tablets orally every 12 hours for 16 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for
Description: Matching placebo tablets orally every 12 hours for 16 weeks
Study: NCT04158232

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Method
Description: treatment of mature teeth with apical periodontitis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Method
Description: treatment of mature teeth with apical periodontitis
Study: NCT02935725

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose AUT00206 800mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose AUT00206 2000 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ketamine

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Study: NCT02313376

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GAP3KO
Description: GAP3KO administered via the bite of 150-200 GAP3KO-infected A. stephensi mosquitoes under controlled conditions.
Study: NCT04782336

Intervention type: OTHER
Group type: OTHER
Intervention: Sample Collection
Description: Sample Collection - Adult Population:~* Two (2) Nasal AND/OR~* Two (2) Throat Swabs AND/OR~* One (1) Saliva Sample~Sample Collection - Paediatric Population:~* Two (2) Nasal OR~* Two (2) Throat Swabs AND/OR~* One (1) Saliva Sample